Is Type-2 Diabetes a Glycogen Storage Disease of Pancreatic β-Cells?

Frances M Ashcroft1,*, Maria Rohm1, Anne Clark2, and Melissa F Brereton1

1Department of Physiology, Anatomy and Genetics and OXION, University of Oxford, Parks Road, Oxford OX1 3PT, UK
2Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK

Abstract

Elevated plasma glucose leads to pancreatic β-cell dysfunction and death in type 2 diabetes. Glycogen accumulation, due to impaired metabolism, contributes to this ‘glucotoxicity’ via dysregulated biochemical pathways promoting β-cell dysfunction. Here, we review emerging data, and re-examine published findings, on the role of glycogen in β-cells in normoglycaemia and in diabetes.

Keywords

glycogen; diabetes; pancreatic β-cell; insulin

Introduction

Glucose metabolism is an essential step in glucose-stimulated insulin secretion from the pancreatic β-cell and metabolic dysfunction is believed to contribute to impaired insulin release in type 2 diabetes. Although glycogen is not normally present in β-cells, substantial amounts are accumulated by β-cells under hyperglycaemic conditions. Nevertheless, its physiological and pathophysiological roles are controversial, and how metabolism drives its accumulation is not fully understood.

Several special features of β-cell metabolism underpin its ability to serve as a glucose sensor and match insulin secretion to the circulating glucose level (Prentki et al., 2013; Schuit et al., 2001). First, glucose uptake by the β-cell is not rate limiting which ensures rapid equalisation of intracellular and extracellular glucose concentrations (Matschinsky and Ellerman, 1968; Thorens, 2015). In rodents, glucose uptake is mediated by the high capacity, low affinity glucose transporter GLUT2. Human β-cells express ~100-fold less GLUT2 than rodent β-cells, with GLUT1 and GLUT3 (which have a low Km) being the major glucose transporters (De Vos et al., 1995). Nevertheless, despite these differences in glucose transporters, the rate-limiting step in glucose metabolism in both species is the
phosphorylation of glucose to glucose-6-phosphate. This reaction is catalysed by glucokinase, which has a high $K_m$ and is not subject to product inhibition (Ashcroft and Randle, 1970; Matschinsky, 1996).

Almost all glucose entering the $\beta$-cell is oxidised via glycolysis and mitochondrial oxidative phosphorylation to ATP (Prentki et al., 2013; Schuit et al., 2001). Little is metabolized to lactate because lactate dehydrogenase activity is very low in $\beta$-cells (Sekine et al., 1994) and expression of the monocarboxylate transporter MCT1 (Slc16a1) is suppressed (Lemaire et al., 2016; Zhao et al., 2001). The absence of these ‘disallowed’ genes is necessary to prevent triggering of insulin secretion during exercise by circulating pyruvate or lactate – indeed, expression of MCT1 in human $\beta$-cells (due to a mutation in its promoter) leads to exercise-induced hypoglycaemia (Otonkoski et al., 2003). Under normal conditions, glycogen synthesis accounts for <10% of glucose uptake, the conversion of glucose to lipids and amino acids is of minor quantitative significance, and the sorbitol and pentose phosphate pathways are relatively unimportant (Ashcroft et al., 1972). As a consequence, glucose oxidation closely matches glucose consumption, and ATP levels rise in response to an increase in extracellular glucose (Ashcroft et al., 1973; Detimary et al., 1996). This leads to closure of plasmalemmal $K_{\text{ATP}}$ channels, which triggers membrane depolarisation, $Ca^{2+}$-influx and insulin release (Ashcroft, 2007).

Although $\beta$-cells have the ability to store glycogen and lipid, both are almost completely absent under normoglycaemic conditions. Nevertheless, it has been known for many years that large amounts of glycogen accumulate in $\beta$-cells in diabetes (Toreson, 1951). Why this is the case is not fully established and its functional role is controversial. On the one hand, it has been argued that glycogen metabolism by $\beta$-cell is not involved in glucose homeostasis and that its accumulation is not sufficient to trigger $\beta$-cell loss or dysfunction (Mir-Coll et al., 2016). On the other, that glycogen accumulation in diabetes may reflect an underlying metabolic dysfunction and lead to a reduction in $\beta$-cell mass (Brereton et al., 2016; Malaisse, 2016; Malaisse et al., 1992). Here, we review recent evidence that glycogen storage may contribute to $\beta$-cell dysfunction in type-2 diabetes.

Identification of $\beta$-Cells as a Glycogen Storing Tissue

It was discovered over 60 years ago that glycogen accumulates in $\beta$-cells of diabetic patients (Toreson, 1951). This gives rise to a characteristic vacuolated appearance of the cytoplasm, that was initially termed ‘hydropic degeneration’ (Weichselbaum and Stangi, 1901). Glycogen was subsequently identified in $\beta$-cells in multiple animal models of diabetes or hyperglycaemia (Hellman and Idahl, 1969; Idahl and Hellman, 1968; Lazarus and Volk, 1958; Malaisse et al., 1967; Matschinsky and Ellerman, 1968; Ravelli et al., 2013; Williamson, 1960), and shown to accumulate in $\beta$-cell lines and islets isolated from wild-type mice and normoglycaemic human donors when cultured at high glucose (Andersson et al., 2016; Brereton et al., 2016; Malaisse et al., 1992). Glycogen can also be observed in islets from Type 2 diabetic donors (Figure 1). However, it is not found under normoglycaemic conditions (Brereton et al., 2016; Malaisse et al., 1967; Ashcroft et al., 1972).
Despite its identification many years ago, the presence of glycogen in β-cells is often overlooked. This is because its detection is challenging as it is rapidly degraded and washed out of cells during tissue fixation and processing for histochemistry (Graf and Klessen, 1981). It also quickly disappears if islets (Malaisse et al., 1992) or INS-1 cells (Andersson et al., 2016) exposed to chronic hyperglycaemia are subsequently cultured under normoglycaemic conditions. As a consequence, glycogen-containing β-cells have often been missed. Indeed, it seems likely that β-cells that appear (or are described as) “clear”, “vacuolated” or “empty” in animal models of diabetes (Cinti et al., 2016; Jung et al., 2008; Poudel et al., 2015; Talchai et al., 2012) or in human diabetes (Poudel et al., 2015) may originally have contained glycogen that was subsequently lost during fixation and processing.

In contrast to β-cells, glycogen is not detected in α-cells or δ-cells of islets from diabetic patients, diabetic animal models, or non-diabetic human donors cultured at high glucose (Brereton et al., 2016; Graf and Klessen, 1981). Why this is the case is unknown. It is possible that α-cells take up less glucose than β-cells in response to hyperglycaemia, that they metabolise glucose differently (Schuit et al., 1997) or that they lack some part of the biochemical machinery needed to manufacture and store glycogen.

**Regulation of Glycogen Metabolism**

Pancreatic β-cells express many of the key enzymes involved in glycogen synthesis and degradation, including phosphoglucomutase, UDP-pyrophosphorylase, the muscle isoform of glycogen synthase (GS) *GYS1*, glycogen branching enzyme (*Gbe1*) and glycogen phosphorylase (GP) (Andersson et al., 2016; Brereton et al., 2016; Brolin and Berne, 1970; Newman, 1977) (Figure 2A). The activity of most of these enzymes in β-cells is relatively low compared to liver and muscle, (Andersson et al., 2016; Brolin and Berne, 1970; Newman, 1977). However, GS is activated (and GP inactivated) when glucose is elevated (Zhang et al., 1994). At least part of this increase is due to allosteric activation by glucose metabolites: glucose-6-phosphate, for example, is a potent activator of glycogen synthase (Bouskila et al., 2010; Villar-Palasi and Guinovart, 1997) (Figure 2A,B).

Hyperglycaemia not only increases substrate availability, it also enhances the expression of key genes involved in glycogen synthesis, such as *Ppp1r3c;* or PTG (protein targeting to glycogen) (Bensellam et al., 2009; Brereton et al., 2016). This protein is a regulatory subunit of protein phosphatase 1 (PP1) and acts as a molecular scaffold that links it to glycogen, thereby activating GS and inhibiting GP. PTG overexpression drives glycogen formation in neurones (Vilchez et al., 2007), sertoli cells (Villarroel-Espindola et al., 2016), adipocytes (Greenberg et al., 2003), cancer cells (Shen et al., 2010) and β-cells (Mir-Coll et al., 2016), and its heterozygous deletion leads to reduced glycogen stores in liver, heart, muscle and adipose tissue (Crosson et al., 2003). Increased PTG mRNA is also associated with increased glycogen content in β-cells from diabetic mice (Bensellam et al., 2009; Brereton et al., 2016; Mir-Coll et al., 2016). Interestingly, a polymorphism in the *PPIR3C* gene is associated with a 3.6-fold increased risk of developing type-2 diabetes (Wang et al., 2001).
The extent of glycogen accumulation is both glucose- and time-dependent (Andersson et al., 2016; Brereton et al., 2016; Matschinsky and Ellerman, 1968). In an inducible mouse model of diabetes, 2 weeks of severe hyperglycaemia (>20mM) was required for substantial glycogen stores to form. In vitro, however, 48h exposure to high glucose was sufficient for INS-1 cells, and β-cells in islets isolated from normoglycaemic mice or non-diabetic human donors to accumulate significant glycogen (Andersson et al., 2016; Brereton et al., 2016; Mir-Coll et al., 2016). Thus the rate of glycogen accumulation may vary between the in vitro and in vivo situation. It is also worth noting that the glucose concentration at which human and rodent islets are often cultured (11 to 25mM) is not normoglycaemic, and leads to significant glycogen formation (Brereton et al., 2016; Andersson et al., 2016).

Glycogen accumulation appears to be triggered not only by increased substrate, but also by changes in β-cell metabolism caused by chronic hyperglycaemia. Hyperglycaemia both in vitro and in vivo, is associated with marked changes in the expression of β-cell metabolic genes: expression of enzymes in the Krebs cycle and oxidative phosphorylation are reduced, and glycolytic, gluconeogenic and glycogen metabolising enzymes are increased (Bensellam et al., 2009; Brereton et al., 2016; Brun et al., 2013; Jonas et al., 1999). Expression of mitochondrial carrier proteins, that transfer metabolites across the mitochondrial membrane, is modified, contributing to metabolic dysfunction (Brun and Maechler, 2016). Down-regulation of genes involved in mitochondrial metabolism is also seen in transcriptome analysis of β-cells from type 2 diabetic donors (Marselli et al., 2010; Segerstolpe et al., 2016). Furthermore, the glucose-stimulated increase in ATP production is absent in islets from animal models of diabetes (Brereton et al., 2016) or human donors with type-2 diabetes (Anello et al., 2005). In addition, islets exposed to chronic hyperglycaemia in vitro release insulin in response to tolbutamide but not glucose, consistent with the idea that the impairment in glucose-induced stimulus-secretion coupling lies upstream of K_ATP channel closure (Henquin et al., 2015).

The trigger for altered β-cell metabolism may not be elevation of glucose per se but rather an increase in one or more of its metabolites. Glycogen accumulation is also found in β-cells from mice expressing an activating mutation (Y214C) in glucokinase (Brereton et al., 2016), which are hypo- not hyper-glycaemic (Tornovsky-Babeay et al., 2014). This mutation is predicted to result in elevation of G-6-P, and thereby contribute to activation of glycogen synthase and glycogenesis (Bouskila et al., 2010).

In summary, the available data suggest that altered β-cell glucose metabolism contributes to dysregulated insulin secretion. Since other pathways for glucose metabolism are limited, the excess glucose entering the β-cell in type 2 diabetes is diverted from oxidative metabolism to glycogenesis. Thus glycogen can be considered a marker for impaired β-cell metabolism.

**Glycogen Rapidly Disappears on Euglycaemia**

β-cell glycogen stores are rapidly dissipated when euglycaemia is restored, via both metabolic degradation and glycophagy. The former, which takes place in the cytoplasm, involves the enzymes glycogen phosphorylase and glycogen debranching enzyme, whereas the latter is mediated via the autosomal/lysosomal route. In isolated islets, the rate of
Glycogenolysis is related to the glycogen content (Malaisse et al., 1992), and in mice with an activating K$_{\text{ATP}}$ channel mutation that led to substantial glycogen accumulation, glycogen stores vanished within 24h of establishing euglycaemia in vivo (Brereton et al., 2016). In this model, the anti-diabetic sulphonylurea drug glibenclamide was more effective than insulin (Brereton et al., 2016), perhaps because, in addition to normalising blood glucose, it stimulated Ca$^{2+}$-dependent electrical activity. The enhanced Ca$^{2+}$ influx would facilitate glycogen degradation by stimulating glycogen metabolising enzymes (Denton, 2009; Liu et al., 2008).

Glycogen can also be degraded by autophagy in a process known as ‘glycophagy’ (Kondomerkos et al., 2005; Kotoulas et al., 2006; Mellor et al., 2014). Glycophagy is a route for glycogen degradation in both mouse and human β-cells, as substantial numbers of glycogen particles can be found within autophagosomes and lysosomes (Figure 1) (Brereton et al., 2016). It may be significant that the number of autophagosomes does not change during hyperglycaemia, but is markedly enhanced following restoration of normoglycaemia, when glycogen stores are dissipated (Brereton et al., 2016).

In the liver, glycogen breakdown results in the release of glucose into the circulation. In contrast, muscle does not metabolise glycogen to free glucose as it lacks the enzyme glucose-6-phosphatase (G6Pase). β-cells do express G6Pase (Ashcroft et al., 1970; Brereton et al., 2016; Segerstolpe et al., 2016), but it is a different isoform and its activity is substantially less than that in liver (Ashcroft and Randle, 1968; Matschinsky and Ellerman, 1968). Its function in β-cells is largely unknown. Knockout of G6pc2 (the major islet G6Pase) in mice leads to enhanced basal insulin secretion and reduced fasting blood glucose (Pound et al., 2013), and a polymorphism in the human G6PC2 gene is associated with elevated fasting plasma glucose (Bouatia-Naji et al., 2008). Expression of G6pc2 is downregulated by hyperglycaemia (Brereton et al., 2016).

Interestingly, there is a paradoxical transient (~5min) increase in insulin release from both rodent and human islets previously incubated at high glucose, immediately upon glucose reduction (Henquin et al., 2015; Malaisse et al., 1993; Malaisse et al., 1967; Malaisse et al., 1977). This has been attributed to a rapid increase in glycogenolysis, and the duration of increased insulin secretion has been proposed to reflect the time taken to dissipate the glycogen stores (Malaisse et al., 1993) (Figure 2C). Whereas in normal islets, a fall in extracellular glucose is accompanied by a parallel fall in glycolytic flux, this was not the case in islets isolated from hyperglycaemic rats despite a marked decrease in the contribution of exogenous glucose to metabolism (Malaisse et al., 1993). This suggests that glycogenolysis may interfere with glycolysis, and provide an intracellular substrate for metabolism that enhances K$_{\text{ATP}}$ channel closure and insulin secretion. However, this interesting idea requires further testing under controlled conditions of intra and extra-cellular glucose and measurement of glycogen flux.

An Emerging Role for Glycogen in the Pathophysiology of Diabetes

Type-2 diabetes mellitus is characterised by inappropriate insulin release from the pancreatic β-cell, which results in chronically elevated blood glucose levels. This further impairs β-cell
function, exacerbating the diabetes, and ultimately leads to complications such as retinopathy, nephropathy, neuropathy and macro- and micro-vascular disease. This phenomenon is referred to as ‘glucotoxicity’. Why hyperglycaemia is detrimental to the β-cell and to other tissues is not clearly established. Given that β-cells accumulate glycogen in diabetes, often in very substantial amounts, a salient question is what impact glycogen storage has on β-cell function and whether it is protective or deleterious.

In astrocytes, a substantial fraction of glucose is normally metabolised via glycogen production and breakdown (Walls et al., 2009). Similarly, although neurones do not use glycogen as an energy store, they synthesize and break down tiny amounts of it continuously and upregulation of this process in hypoxia is important for neuronal survival (Saez et al., 2014). Whether glycogen shunting exists in β-cells is not established. It seems unlikely to be important in β-cells under physiological conditions, as knockout of GS had no effect on glucose homeostasis in non-diabetic mice (Mir-Coll et al., 2016). Nevertheless, it remains possible that it plays a role in hypoxia by promoting β-cell survival, as in neurones. Under hyperglycaemic conditions, inhibition of oxidative metabolism may activate the same pathway and precipitate glycogen accumulation. Initially, this may help protect the cell from glucose-induced generation of reactive oxygen species, as has been suggested for various types of cancer cell (Zois and Harris, 2016). Whether this is actually the case, however, requires investigation.

Excessive glycogen accumulation, however, appears to be detrimental. Mouse pancreatic β-cells containing substantial glycogen stores showed increased apoptosis, whereas β-cells that did not contain glycogen were protected (Brereton et al., 2016). Likewise, α-cells, which did not contain glycogen, were protected. β-cell apoptosis appears to result from the enhanced glycogen content, rather than hyperglycaemia per se, as manipulations that lower glycogen levels prevent caspase 3 activation (one of the first steps in apoptosis), despite the elevated glucose (Brereton et al., 2016). No apoptotic changes were found in mouse β-cells in vivo following overexpression of PTG (Mir-Coll et al., 2016). However, these mice were normoglycaemic and glycogen was only elevated 3.5-fold, suggesting that glycogen must reach a higher concentration before it has adverse effects. This raises the question of whether excessive glycogen accumulation might lead to β-cell death in type-2 diabetes and contribute to the reduced β-cell mass found in some patients. If this proves to be the case, ways to prevent its accumulation might provide a novel target for therapeutic drugs. In this respect, it may be significant that metformin decreases glycogen accumulation in INS-1 cells exposed to hyperglycaemia (Brereton et al., 2016).

Dissipation of glycogen stores on return to euglycaemia might also contribute to inappropriately elevated fasting insulin levels and so aggravate hypoglycaemia (Malaisse et al., 1993). In type-2 diabetes fluctuating blood sugar concentrations are common, with sustained periods of hyperglycaemia alternating with normal or low blood glucose levels. The experimental data suggests that endogenous insulin secretion may be greater than expected when sustained hyperglycaemia is reduced (by insulin or drugs); at the low glucose concentration, glycogen mobilisation to intracellular G-6-P would act as a substrate for increased metabolism and insulin secretion, thereby predisposing to hypoglycaemia (Figure 2C).
Many tissues affected by the secondary complications of diabetes also both accumulate glycogen and undergo apoptosis. This phenomenon is observed in several animal models of diabetes and affected cells include nephrons, cardiomyocytes, retinal epithelia, and neurones (Gatica et al., 2015; Hernandez et al., 2014; Kang et al., 2005; Reichelt et al., 2013; Vallon and Komers, 2011). Thus it is possible that excessive glycogen accumulation induced by hyperglycaemia, leading to dysfunction and death, is a common pathophysiology that adversely affects many tissues in diabetes.

**Lessons from Glycogen Storage Disorders**

Glycogen accumulation is also found in a number of rare genetic disorders caused by defects in enzymes involved in its synthesis or degradation (Hicks et al., 2011; see also www.OMIM.org). More than 12 different types of glycogen storage disease (GSD) are known. The effects of these disorders are manifested in different organs dependent upon the different enzyme isoforms present (for review, see Hicks et al., 2011), and their differential regulation in different tissues (Zois and Harris, 2016).

Glycogen storage disease Type 1 (von Gierke’s disease) is most commonly due to a mutation in *G6PC1* (glucose-6-phosphatase 1), which catalyses the terminal step of gluconeogenesis. Consequently, its loss leads to glycogen accumulation, primarily in the liver. This gene is not expressed at any significant level in β-cells, which explains why they are unaffected in this disease. Nevertheless, it is of interest that downregulation of the β-cell isoform *G6PC2* occurs in diabetes (Brereton et al., 2016), which is also expected to enhance glycogen accumulation.

Pompe’s disease (GSD2) results from a deficiency of the enzyme acid alpha-glucosidase (*GAA*), which is required for lysosomal degradation of glycogen. This leads to accumulation of structurally normal glycogen in lysosomes of affected cells, which is toxic. Accumulation of insoluble, hyperphosphorylated and poorly branched glycogen occurs in Lafora disease, which is caused by mutations in laforin or malin. It is proposed this leads to impaired autophagy and thereby induces neuronal apoptosis (Duran et al., 2014). Glycogen is also observed in lysosomes of hyperglycaemia mice and patients with type 2 diabetes (Brereton et al., 2016) (Figure 1). However, it is not yet clear whether this represents impaired glycophagy or simply reflects the presence of excess glycogen in the cell.

Both Andersen’s disease (GSD4) and Cori’s disease (GSD3) are characterised by large amounts of abnormal glycogen in the cell. GSD3 results from mutations in the glycogen debranching enzyme AGL, resulting in accumulation of abnormal glycogen with short outer chains. GSD4 is due to a deficiency in glycogen debranching enzyme (Gbe1) and leads to the massive build-up of unbranched glycogen, which results in lethal liver cirrhosis. Expression of Gbe1 mRNA is enhanced in diabetic mouse islets (Brereton et al., 2016), suggesting accumulation of unbranched glycogen probably does not occur in diabetes. However, as downregulation of enzymatic activity cannot be excluded, this idea needs to be confirmed with a careful analysis of glycogen branching in both rodent and human islets.
Other forms of GSD are caused by inhibition of glycogen breakdown. McArdle’s disease (GSD5) is due to loss-of-function mutations in the muscle type of glycogen phosphorylase (Pygm), which results in muscle weakness on exercise. Hers disease results from mutations in the liver isoform of glycogen phosphorylase (Pygl, GSD6) or phosphorylase kinase (GSD8), and has a relatively benign phenotype. Both Pygm and Pygl are expressed in β-cells (Andersson et al., 2016; Brereton et al., 2016) but there is no evidence of a β-cell phenotype in GSD5 or GSD6. It seems possible that this is because glycogen only accumulates in β-cells under hyperglycaemic conditions.

Fanconi-Bickel syndrome (GSD11) is caused by mutations in SLC2A2 (GLUT2) and these patients display disturbances of hepatic and renal glucose metabolism but, interestingly, no defects in insulin secretion. This may be because of the dominance of GLUT 1 and GLUT3 in human β-cells. Other types of glycogen storage disease result from mutations in glycolytic enzymes, such as phosphofructokinase (GSD7, in muscle) and aldolase A (GSD12, in muscle and red blood cells). The isoforms involved are cell specific and do not lead to diabetes. However, they demonstrate that inhibition of glucose metabolism may lead to glycogen accumulation. This supports the view that impaired β-cell metabolism (due to hyperglycaemia) may lead to glycogen accumulation in diabetes.

A common feature of glycogen storage diseases is that excessive glycogen accumulation is often fatal for the cell. Why glycogen is toxic to cells, and the threshold concentration for impaired viability, remain unresolved. Similarly, the mechanism(s) underlying glycogen-induced dysfunction and cell death are unclear. Suggestions include impaired autophagy (Duran et al., 2014), aberrant mitochondrial metabolism (Villarroel-Espindola et al., 2016) and accumulation of abnormally branched glycogen (Duran et al., 2012; Valles-Ortega et al., 2011). Reduced cellular ATP levels might also contribute, as glycogen synthesis consumes two molecules of ATP, and futile cycling between glycogen synthesis and breakdown may also occur. Potentially, this might contribute to the failure of glucose to elevate ATP levels in diabetic β-cells (Anello et al., 2005; Brereton et al., 2016). Impairment of normal autophagic and lysosomal processes is also apparent in glycogen-containing islets (Brereton et al., 2016) and loss of autophagy in mouse β-cells induced by deletion of Atg7 enhanced apoptosis and induced ‘vacuolar’ changes that likely reflect glycogen accumulation (Jung et al., 2008). Why glycogen causes β-cell toxicity, and how long and how high glucose must be elevated to produce toxic levels of glycogen in β-cells, is a matter for future investigation.

Conclusions and Future Perspectives

It is clear that whilst β-cells do not store glycogen under normoglycaemic conditions, they can accumulate substantial amounts in response to hyperglycaemia. This appears to require a triad of stressors: elevated plasma glucose (or G-6-P), upregulation of PTG and impaired oxidative metabolism.

Understanding why glycogen is accumulated, and how it impacts on β-cell viability and insulin secretion is now a priority. This knowledge also has implications for emerging type-2 diabetes therapies including glucokinase activators (Matschinsky, 2009) and glycogen phosphorylase inhibitors (Praly and Vidal, 2010), which would promote glycogen formation.
and may thereby impact β-cell function. A detailed understanding of how β-cell metabolism is altered in diabetes is also crucial.

Acknowledgements

We thank Patrik Rorsman for much valuable discussion. We are very grateful to Patrick McDonald, Jocelyn Manning Fox and James Lyon of the Alberta Diabetes Institute, Edmonton, Canada for supplying the pancreatic islets isolated from a type 2 diabetic donor illustrated in Figure 1. Work in our own laboratory referred to here was supported by the Wellcome Trust (grant nos 884655, 089795), and the European Research Council (ERC Advanced grant 322620). MFB held a Wellcome Trust OXION Training fellowship. MR was supported by a Novo Nordisk postdoctoral fellowship run in partnership with the University of Oxford. FMA held a Royal Society/Wolfson Merit Award and an ERC Advanced Investigatorship.

References


Cell Metab. Author manuscript; available in PMC 2018 April 09.


Figure 1. Glycogen is present in human β-cells in diabetes
Representative electron micrograph showing glycogen in a β-cell of a type-2 diabetic organ donor with diet-controlled diabetes (HbA1c, 6.6) for 10 years. Sample prepared and stained for glycogen (Brereton et al 2016). Glycogen particles (gly, electron dense material) were distributed throughout the cytoplasm in most β-cells. Autophagic bodies and lysosomes (inset, lys) also contained glycogen. Insulin granules (Ins) contained either dark crystalline cores (mature) or less electron dense material (immature). Scale bar, 1µM. Scale bar of inset 0.5µM.
Figure 2. Pathways for glycogen accumulation and its effects in β-cells
A. Key pathways for glycogen synthesis and degradation. GCK, glucokinase. G6PC2, glucose-6-phosphatase. PGM1, phosphoglcomutase. GYG1, glycogenin. GYS1 GYS2, glycogen synthase. PTG protein targetting to glycogen (a subunit of PKA). GBE1, glycogen branching enzyme. PYGL.M, glycogen phosphorylase muscle (PYGM) and liver (PYGL) types. AGL (amylo-α-1,6-glucosidase, 4-α-glucanotransferase), glycogen debranching enzyme.

Cell Metab. Author manuscript; available in PMC 2018 April 09.
B.C. Diagrammatic representation of the effects of glycogen accumulation in β-cells. (B) In chronic hyperglycaemia (as in type 2 diabetes) oxidative metabolism of glucose is reduced, leading to decreased insulin release. Glucose continues to enter the cell and is converted to glucose-6-phosphate (G-6-P) by glucokinase. Elevation of G-6-P leads to allosteric activation of glycogen synthase (GS) and increased expression of Protein Targeting to Glycogen (PTG), resulting in glycogen accumulation. Continued glycogen accumulation can lead to activation of apoptotic mechanisms and cell death. Pathways amplified in chronic hyperglycaemia are indicated in red.

(C) When extracellular glucose is reduced, glycogen is metabolised via glycogen phosphorylase (GP) to G-6-P, which, via restored oxidative metabolism, leads to enhanced ATP production, resulting in inappropriately elevated insulin secretion. Pathways amplified on restoration of blood glucose are indicated in red.